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 42 
Abstract 43 
COPD and asthma prevalence is associated with socioeconomic status (or 44 
‘deprivation’), yet deprivation is rarely considered in typical large-scale efficacy 45 
randomised controlled trials that recruit highly selected patient populations. In this 46 
post hoc analysis of the Salford Lung Studies in COPD and asthma — two 12-47 
month, open-label, effectiveness randomised controlled trials conducted in UK 48 
primary care — we evaluated the impact of patient deprivation on clinical outcomes 49 
with initiating fluticasone furoate/vilanterol versus continuing usual care.  50 
Patients were categorised into deprivation quintiles based on postcode and a 51 
countrywide database of indices of deprivation, and trial outcomes by quintile were 52 
assessed.  53 
Fifty-two percent of patients in the COPD study were included in the most 54 
deprived quintile, contrasting with 20% in the asthma study. Greater deprivation was 55 
associated with higher rates of primary/secondary healthcare contacts and costs. 56 
However, the treatment effect of fluticasone furoate/vilanterol versus usual care for 57 
primary (COPD: moderate/severe exacerbations; asthma: Asthma Control Test 58 
responders at week 24) and secondary/other (healthcare consumption, adherence, 59 
treatment modifications, study withdrawals, exacerbations, serious adverse events) 60 
outcomes was similar across deprivation quintiles.  61 
Our findings support the recruitment of participants from all socioeconomic 62 
strata to allow assessment of data generalisability to routine clinical practice.  63 
GlaxoSmithKline plc. studies: HZC115151/NCT01551758; 64 
HZA115150/NCT01706198. 65 
 66 
 67 
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Introduction 68 
Socioeconomic status is a key determinant of health outcomes [1]. The prevalence of 69 
chronic obstructive pulmonary disease (COPD), which is generally regarded as a 70 
disease of deprivation, and asthma tends to be higher in more deprived areas [2, 3]. 71 
Deprived patients may be under-represented in traditional randomised controlled 72 
trials (RCTs), which seldom, if ever, collect and report the socioeconomic status of 73 
their participants. Evidence suggests that only a limited proportion of patients with 74 
COPD or asthma are eligible for typical large efficacy RCTs [4–6]; thus, generalising 75 
trial findings to the broader population of patients seen in routine clinical practice 76 
(including deprived patients) is problematic. 77 
The Salford Lung Studies (SLS) were pragmatic randomised trials in COPD and 78 
asthma set in routine clinical practice in the United Kingdom (UK) [7, 8]. The SLS 79 
provided a unique opportunity to explore the frequency of deprivation in pragmatic 80 
RCTs and whether deprivation impacts the trial outcomes. 81 
 82 
Methods  83 
Patients and study design 84 
The SLS in COPD and asthma were concurrent, prospective, 12-month, open-label 85 
RCTs that evaluated the clinical effectiveness and safety of initiating fluticasone 86 
furoate/vilanterol (FF/VI) versus continuing usual care (UC) for the treatment of 87 
COPD and asthma, respectively (SLS COPD: NCT01551758 and SLS asthma: 88 
NCT01706198). The studies were conducted in primary care practices across 89 
Salford and South Manchester, UK. The trial designs and primary results have been 90 
reported previously [7, 8]. Recruitment for SLS COPD preceded that of SLS asthma. 91 
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Patient recruitment commenced in Salford, later extending to sites in more affluent 92 
areas of South Manchester. 93 
Briefly, patients in SLS COPD were aged ≥40 years, had a general practitioner’s 94 
(GP’s) diagnosis of COPD, had experienced ≥1 exacerbations of COPD in the prior 3 95 
years and were receiving regular maintenance inhaler therapy [7]. Patients in SLS 96 
asthma were aged ≥18 years, had a documented GP’s diagnosis of symptomatic 97 
asthma and were receiving regular maintenance inhaler therapy [8]. Both trials had 98 
minimal exclusion criteria. In both studies, patients were randomised 1:1 to initiate 99 
once-daily inhaled FF/VI 100 µg/25 µg (or 200 µg/25 µg for some patients in SLS 100 
asthma, according to GP assessment) or to continue with optimised UC as 101 
prescribed by their GP. Randomisation was stratified in SLS COPD by the 102 
presence/absence of a COPD exacerbation in the previous 12 months and baseline 103 
intended maintenance therapy (long-acting beta2-agonist [LABA], long-acting 104 
muscarinic antagonist [LAMA] or LABA/LAMA; inhaled corticosteroid [ICS], 105 
ICS/LABA or ICS/LAMA; ICS/LAMA/LABA) and in SLS asthma by baseline Asthma 106 
Control Test (ACT) total score (≤15; 16–19; ≥20) and baseline intended maintenance 107 
therapy (ICS or ICS/LABA). Both studies had a 12-month follow-up period. 108 
Treatment modifications were permitted at GPs’ discretion throughout the studies 109 
(patients could switch from FF/VI to UC but not vice versa). To minimise disruption to 110 
patients’ everyday lives and preserve the real-world nature of the trials, there were 111 
few protocol-mandated visits (screening, randomisation and 12 months/end of study 112 
visit only); patients were additionally contacted by telephone at the 3-, 6- and 9-113 
month time points for assessment of safety (both trials) and outcome questionnaire 114 
assessments, including ACT (SLS asthma only). Medications were dispensed as 115 
usual by local community pharmacies, and data were captured remotely and 116 
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continuously via patients’ electronic health records using a primary/secondary care-117 
linked database system [7, 8]. 118 
 119 
Assessment of patient deprivation 120 
A deprivation score for each patient was calculated using patient-level postcodes 121 
and a countrywide database of indices of deprivation (version 2010) [9]. This 122 
database ranks all areas in England based on their relative level of deprivation, as 123 
measured using 38 separate indicators organised across seven distinct domains. 124 
Domains can be combined and weighted to produce a single overall Index of Multiple 125 
Deprivation, which is used to rank every small area in England according to the 126 
deprivation experienced by the people living there [9]. 127 
Deprivation scores were used to produce quintiles (quintile 1 being the most 128 
deprived and quintile 5 the least deprived).  129 
 130 
Outcome measures 131 
These post hoc analyses of patient deprivation focused on the primary effectiveness 132 
outcome measures analysed in the main trials, as reported in the primary SLS 133 
papers [7, 8]. For SLS COPD, the primary effectiveness outcome was the mean 134 
annual rate of moderate/severe exacerbations, defined as any worsening of 135 
respiratory symptoms necessitating treatment with antibiotics or systemic 136 
glucocorticoids (i.e. moderate exacerbations), or hospitalisation due to a COPD 137 
exacerbation (i.e. severe exacerbations). For SLS asthma, the primary effectiveness 138 
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outcome was the percentage of ACT responders (patients who achieved an ACT 139 
total score ≥20 and/or an increase from baseline ≥3) at week 24. The percentage of 140 
ACT responders was also assessed at weeks 12, 40 and 52. 141 
Several secondary/other outcomes were also evaluated, including number of 142 
primary/secondary care contacts (PCCs/SCCs), total direct COPD-/asthma-related 143 
healthcare costs, treatment adherence (as estimated by the proportion of days 144 
covered [PDC] based on study medication prescribing data captured during the 145 
study), treatment modifications, patient withdrawals from study, rates of severe 146 
asthma exacerbations (SLS asthma only) and incidence of serious adverse events 147 
(SAEs; including the pre-specified pneumonia SAE of special interest). Details of 148 
outcome measures and their evaluation have been reported previously [7, 8]. 149 
 150 
Statistical analyses 151 
Analyses of outcomes by deprivation quintile were performed as intent-to-treat (ITT; 152 
per randomised treatment group) in the total population, which comprised all 153 
randomised patients who received ≥1 prescription of study medication. The primary 154 
effectiveness outcome for each study was also examined in the primary 155 
effectiveness analysis (PEA) population, comprising all patients who had 156 
experienced ≥1 exacerbation of COPD in the year prior to randomisation (SLS 157 
COPD) or who had an ACT total score <20 at the randomisation visit (SLS asthma). 158 
For SLS asthma, outcomes by deprivation quintile were additionally analysed in the 159 
ICS/LABA therapy subset, which comprised patients whose baseline asthma 160 
maintenance therapy per randomisation stratification and pre-randomisation 161 
prescription was an ICS/LABA. 162 
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In these post hoc analyses, the primary effectiveness endpoint for each study was 163 
analysed according to the method reported in the respective primary publication [7, 164 
8], but with the inclusion of deprivation quintile and its interaction with randomised 165 
treatment group in each statistical model. For SLS COPD, the primary effectiveness 166 
endpoint (mean annual rate of moderate/severe COPD exacerbations) was analysed 167 
using a general linear model assuming a negative binomial distribution. Least 168 
squares (LS) mean annual rates, treatment ratios and 95% confidence intervals (CIs) 169 
by deprivation quintile are presented. For SLS asthma, the primary effectiveness 170 
endpoint (percentage of ACT responders at week 24) was analysed using logistic 171 
regression. Adjusted odds ratios and 95% CIs for FF/VI versus UC are presented by 172 
deprivation quintile. ACT responder analyses were additionally conducted at weeks 173 
12, 40 and 52. 174 
Healthcare resource utilisation data are described as the mean combined annual 175 
rates of PCCs/SCCs for FF/VI and UC by deprivation quintile. The interaction of 176 
deprivation with treatment effect on PCC/SCC rates was evaluated using a general 177 
linear model. Geometric mean total COPD/asthma care costs (costs for COPD-178 
/asthma-related healthcare, rescue medication and study drugs) are presented by 179 
deprivation quintile and randomised treatment group.  180 
Data for treatment modifications, treatment adherence (PDC) and study withdrawals 181 
are summarised by deprivation quintile and randomised treatment group. 182 
The statistical analysis of rates of on-treatment severe asthma exacerbations by 183 
randomised treatment group and deprivation quintile was conducted using a general 184 
linear model. LS mean annual rates, treatment ratios and 95% CIs are presented. 185 
The treatment effect of FF/VI versus UC on pneumonia SAE rates by deprivation 186 
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quintile was analysed using a negative binomial regression model. LS mean annual 187 
rates, treatment ratios and 95% CIs are presented.  188 
The overall aim of this post hoc exploratory work was to establish trends and/or 189 
consistency across deprivation quintiles on the outcomes of interest. As such, no 190 
adjustments for multiplicity were performed.  191 
 192 
Results 193 
In SLS COPD, 52% of patients (1453/2791) were in the most deprived quintile by 194 
postcode, whereas in SLS asthma, deprivation was more equally distributed with 195 
only 20% of patients (855/4218) in the most deprived quintile (figure 1). When 196 
analysed according to investigators who recruited to both SLS COPD and SLS 197 
asthma, patient distribution across the deprivation quintiles was similar to that 198 
observed in the overall studies (data not shown).  199 
In SLS COPD, there was a numerical trend toward patients being younger and for 200 
higher proportions of females and current smokers in the more deprived quintiles 201 
relative to the least deprived quintiles (table 1). There was also a trend for higher 202 
body mass index (BMI) in more deprived patients, but the absolute difference across 203 
quintiles may be too small to be clinically relevant. No notable difference in COPD 204 
exacerbation history was observed across the deprivation quintiles. Similar trends 205 
were observed in SLS asthma, where patients in the more deprived quintiles were 206 
numerically more likely to be younger, to smoke, to have a higher BMI, and to have 207 
uncontrolled asthma (ACT total score ≤15) and recent asthma symptoms (rescue 208 
medication use, activity limitations, night-time symptoms/awakenings) relative to 209 
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patients in the less deprived quintiles (table 1). There was no notable difference in 210 
asthma exacerbation history across the deprivation quintiles. Characteristics of 211 
patients in the SLS asthma ICS/LABA therapy subset were generally similar to the 212 
total study population (supplementary table S1). 213 
In SLS COPD, the treatment effect of initiating FF/VI versus continuing UC on the 214 
mean annual rate of moderate/severe exacerbations across deprivation quintiles was 215 
broadly similar to the overall PEA population (figure 2a). In SLS asthma, there was a 216 
consistent benefit for FF/VI over UC for the percentage of ACT responders at week 217 
24 across the deprivation quintiles in the PEA population (figure 2b); a similar benefit 218 
for FF/VI versus UC was also observed at weeks 12, 40 and 52 in each deprivation 219 
quintile in the PEA population (figure 3) and at weeks 12, 24, 40 and 52 in the 220 
ICS/LABA therapy subset of the PEA population (supplementary figure S1). 221 
In both trials, higher rates of PCCs/SCCs were observed in the more deprived 222 
relative to less deprived quintiles (table 2), but there was no apparent interaction of 223 
deprivation quintile with treatment effect for FF/VI versus UC. Care costs were higher 224 
for more deprived patients with COPD, but not for those with asthma. There was no 225 
consistent impact of deprivation on treatment adherence, treatment modification 226 
rates, patient withdrawals from study (tables 3–5) or on-treatment severe asthma 227 
exacerbations (supplementary table S2). There were small differences in the 228 
incidence of on-treatment SAEs between the most and least deprived patients in 229 
both the COPD and asthma studies, but no difference in SAE incidence between 230 
randomised treatment groups in each of the deprivation quintiles. There was no 231 
difference in pneumonia SAE incidence between randomised treatment groups in 232 
each of the deprivation quintiles in SLS COPD (supplementary table S3). In SLS 233 
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asthma, the on-treatment pneumonia SAE incidence was <1% of all patients [10] 234 
and analysis by deprivation quintile was not conducted. 235 
 236 
Discussion 237 
Salford is a typical urban area in North West England and a substantial proportion of 238 
the population live in socioeconomically deprived areas. Over one half of SLS COPD 239 
patients were categorised in the most deprived quintile, compared to 20% of SLS 240 
asthma patients. Higher healthcare resource utilisation and care costs in more 241 
deprived patients could be linked to the observed differences in baseline patient 242 
characteristics (i.e. higher proportions of current smokers, trend for higher BMI in the 243 
more deprived quintiles). Indeed, deprivation has previously been identified as a risk 244 
factor for COPD hospital admissions [11]. The level of deprivation did not influence 245 
any of the main clinical effectiveness and safety outcomes in the SLS, indicating that 246 
the overall trial results are relevant to all patients with asthma and COPD in routine 247 
care. 248 
The major strengths of this study relate to the pragmatic trial design of the SLS, 249 
successful recruitment of patients from all socioeconomic strata and the richness of 250 
the dataset. We were able to access deprivation data for almost all randomised 251 
patients (n>7000) and capture healthcare contacts data using a primary/secondary 252 
care-linked electronic database. Weaknesses include the post hoc nature of these 253 
analyses, which were conducted without multiplicity adjustment. Furthermore, the 254 
high proportion of deprived patients in SLS COPD (in contrast to SLS asthma) 255 
resulted in small sample sizes for some deprivation quintiles, limiting results 256 
interpretation. Another limitation is that patients were allocated into deprivation 257 
quintiles based on ranking of deprivation scores derived by postcode, rather than 258 
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based on individual characteristics. It could be argued, therefore, that patients 259 
allocated to the most deprived quintiles in this study may not necessarily themselves 260 
be truly socioeconomically deprived. Such detailed socioeconomic information was 261 
not available on an individual patient basis in this study. It is noteworthy, however, 262 
that Salford is listed as one of the top 20 local authorities in England with the highest 263 
proportions of areas that are amongst the 10% most deprived [9]; it follows, 264 
therefore, that the SLS likely did include patients who were genuinely of lower 265 
socioeconomic status. 266 
Overall, our data support the view that patients’ socioeconomic status should not be 267 
a barrier to participation in RCTs, and that enrolment of a broad patient population 268 
should be actively encouraged. Routine reporting of data on patients’ baseline 269 
socioeconomic status will allow for assessment of generalisability of trial results in 270 
comparison to patients in routine clinical practice.  271 
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TABLE 1 Patient demographics and baseline characteristics by deprivation quintile for SLS COPD and SLS asthma (total study populations) 
SLS COPD 
 Deprivation quintile# (N=2791) 
Characteristic 
1 
(n=1453) 
2 
(n=601) 
3 
(n=391) 
4 
(n=209) 
5  
(n=137) 
Age, years, mean (SD) 65.0 (9.8) 67.2 (10.1) 68.8 (9.5) 70.4 (8.4) 70.1 (9.5) 
Male, n (%) 733 (50) 305 (51) 197 (50) 111 (53) 78 (57) 
BMI, kg/m2, mean (SD)¶ 28.0 (7.1) 27.9 (6.1) 27.6 (5.4) 27.6 (5.4) 27.1 (5.0) 
Current smoker, n (%) 763 (53) 247 (41) 156 (40) 70 (33) 48 (35) 
Duration of COPD ≥5 years, n (%) 764 (53) 305 (51) 204 (52) 127 (61) 75 (55) 
COPD exacerbations in the year prior to 
randomisation, mean (SD) 
2.1 (2.1) 1.9 (1.8) 2.0 (1.8) 2.0 (1.9) 1.5 (1.4) 
SLS asthma 
 Deprivation quintile# (N=4218) 
 
Characteristic 
1 
(n=855) 
2 
(n=834) 
3 
(n=856) 
4 
(n=831) 
5  
(n=842) 
Age, years, mean (SD) 47.1 (15.8) 47.9 (16.0) 49.9 (16.2) 50.0 (16.9) 54.1 (16.0) 
Male, n (%) 346 (40) 330 (40) 359 (42) 344 (41) 353 (42) 
BMI, kg/m2, mean (SD)¶ 31.0 (7.6) 30.6 (7.1) 30.4 (7.1) 29.1 (6.2) 28.5 (5.8) 
Current smoker, n (%)¶ 276 (33) 218 (26) 179 (21) 108 (13) 65 (8) 
Duration of asthma ≥10 years, n (%) 627 (73) 624 (75) 634 (74) 611 (74)¶ 638 (76) 
Severe asthma exacerbations in the year prior to 
randomisation, mean (SD) 
0.7 (1.2) 0.7 (1.2) 0.7 (1.3) 0.6 (1.0) 0.5 (0.9) 
Uncontrolled asthma (ACT ≤15), n (%) 462 (54)¶ 384 (46) 354 (41) 282 (34) 231 (27) 
Daytime symptoms more than twice a week, n (%)+ 772 (90) 760 (91) 781 (91) 750 (90) 755 (90) 
SABA use more than twice a week, n (%)+ 689 (81) 648 (78) 640 (75) 552 (66) 504 (60) 
Activity limitations in the past week, n (%)+ 501 (59) 474 (57) 454 (53) 374 (45) 351 (42) 
Nocturnal symptoms/awakenings in the past week, n 
(%)+ 
504 (59) 446 (53) 409 (48) 383 (46) 365 (43) 
SLS: Salford Lung Study; COPD: chronic obstructive pulmonary disease; SD: standard deviation; BMI: body mass index; ACT: Asthma Control Test; SABA: 
short-acting beta2-agonist. #: where 1 = most deprived, 5 = least deprived; ¶: based on patients with available data; +: based on patients’ recall of asthma 
symptoms in the past week, as assessed at the baseline (randomisation) visit.  
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TABLE 2 Healthcare contacts# and care costs by deprivation quintile in SLS COPD and SLS asthma (total study populations) 
Deprivation 
quintile¶ 
SLS COPD (N=2791) SLS asthma (N=4218) 
Mean (SD) annual number 
of healthcare contacts+ 
Geometric mean (geometric SD) 
total COPD care costs 
per patient, £§ 
Mean (SD) annual number of 
healthcare contacts+ 
Geometric mean (geometric SD) 
total asthma care costs per 
patient, £§ 
FF/VI 
(n=1396) 
UC 
(n=1395) 
FF/VI 
(n=1396) 
UC 
(n=1395) 
FF/VI 
(n=2105) 
UC 
(n=2113) 
FF/VI 
(n=2105) 
UC 
(n=2113) 
1 n=731 n=722 n=731 n=722 n=412 n=443 n=412 n=443 
 32.0 (23.4) 29.4 (22.2) 842.1 (2.3) 981.4 (2.1) 20.0 (19.0) 18.8 (17.0) 417.3 (1.8) 453.7 (1.9) 
2 n=307 n=294 n=307 n=294 n=434 n=400 n=434 n=400 
 29.7 (21.8) 28.4 (21.8) 742.5 (2.1) 984.1 (2.1) 18.1 (15.0) 18.5 (17.6) 412.9 (1.8) 433.3 (1.9) 
3 n=189 n=202 n=189 n=202 n=401 n=455 n=401 n=455 
 29.9 (19.0) 28.4 (20.3) 819.0 (2.0) 955.2 (2.1) 17.0 (14.8) 17.0 (14.6) 411.0 (1.6) 479.7 (1.9) 
4 n=104 n=105 n=104 n=105 n=425 n=406 n=425 n=406 
 29.2 (19.3) 27.4 (18.6) 730.7 (1.9) 894.8 (2.0) 16.0 (13.7) 13.2 (11.6) 431.3 (1.8) 431.6 (1.9) 
5 n=65 n=72 n=65 n=72 n=433 n=409 n=433 n=409 
 27.5 (22.4) 21.3 (14.9) 743.4 (2.0) 823.6 (1.8) 14.2 (12.6) 13.2 (11.4) 419.7 (1.8) 427.8 (1.8) 
SLS: Salford Lung Study; COPD: chronic obstructive pulmonary disease; SD: standard deviation; FF/VI: fluticasone furoate/vilanterol; UC: usual care. #: on-
treatment, all-cause healthcare contacts; ¶: where 1 = most deprived, 5 = least deprived; +: composite analysis of all primary and secondary healthcare 
contacts; §: including total direct costs for COPD-/asthma-related healthcare resource utilisation, rescue medication and study drugs.  
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TABLE 3 Treatment adherence (PDC) by deprivation quintile in SLS COPD and SLS asthma (total study populations and SLS asthma ICS/LABA 
therapy subset#) 
Mean (SD) PDC, %¶ 
SLS COPD  
(N=2791) 
SLS asthma  
(N=4218) 
ICS/LABA therapy subset  
(N=2642) 
Deprivation 
quintile+ 
FF/VI 
(n=1396) 
UC 
(n=1395) 
Deprivation 
quintile+ 
FF/VI 
(n=2105) 
UC 
(n=2113) 
Deprivation 
quintile+ 
FF/VI 
(n=1319) 
UC 
(n=1323) 
1 (n=1423) 
n=722 
83.8 (23.3) 
n=701 
82.6 (23.0) 
1 (n=848) 
n=410 
78.2 (24.3) 
n=438 
78.9 (25.4) 
1 (n=546) 
n=266 
78.7 (23.5) 
n=280 
76.6 (25.4) 
2 (n=587) 
n=303 
85.4 (21.7) 
n=284 
83.1 (22.9) 
2 (n=829) 
n=432 
79.4 (24.3) 
n=397 
79.0 (25.5) 
2 (n=522) 
n=274 
81.1 (22.9) 
n=248 
78.2 (25.5) 
3 (n=386) 
n=187 
87.5 (20.3) 
n=199 
81.1 (22.3) 
3 (n=849) 
n=399 
82.4 (23.2) 
n=450 
79.9 (24.6) 
3 (n=545) 
n=250 
81.7 (23.7) 
n=295 
77.8 (25.0) 
4 (n=206) 
n=101 
86.8 (21.9) 
n=105 
80.4 (24.7) 
4 (n=823) 
n=422 
85.4 (21.2) 
n=401 
77.2 (25.7) 
4 (n=505) 
n=262 
85.3 (21.6) 
n=243 
76.1 (25.5) 
5 (n=131) 
n=65 
86.1 (19.8) 
n=66 
84.6 (25.3) 
5 (n=833) 
n=426 
85.9 (20.6) 
n=407 
75.8 (27.6) 
5 (n=497) 
n=254 
86.8 (18.9) 
n=243 
73.7 (28.1) 
PDC: proportion of days covered; SLS: Salford Lung Study; COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; LABA: long-acting 
beta2-agonist; SD: standard deviation; FF/VI: fluticasone furoate/vilanterol; UC: usual care; eCRF: electronic case report form. #: the SLS asthma ICS/LABA 
therapy subset comprised patients whose baseline maintenance therapy per randomisation stratification and pre-randomisation prescription was an 
ICS/LABA; ¶: values are mean (SD) PDC based on eCRF study medication prescribing data captured during the study. Based on patients with available PDC 
data (N=2733 for SLS COPD; N=4182 for SLS asthma; N=2615 for SLS asthma ICS/LABA therapy subset); +: where 1 = most deprived, 5 = least deprived.  
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TABLE 4 Treatment modifications by deprivation quintile in SLS COPD and SLS asthma (total study populations and SLS asthma ICS/LABA therapy 
subset#) 
Patients with ≥1 treatment modification during study, n (%) 
 
 
Deprivation 
quintile¶ 
SLS COPD  
(N=2791) 
 
 
Deprivation 
quintile¶ 
SLS asthma  
(N=4218) 
 
 
Deprivation 
quintile¶ 
ICS/LABA therapy subset 
(N=2642) 
FF/VI 
(n=1396) 
UC 
(n=1395) 
FF/VI 
(n=2105) 
UC 
(n=2113) 
FF/VI 
(n=1319) 
UC 
(n=1323) 
1  (n=1453) n=731 
181 (25) 
n=722 
78 (11) 
1  (n=855) n=412 
82 (20) 
n=443 
113 (26) 
1  (n=551) n=268 
62 (23) 
n=283 
80 (28) 
2  (n=601) n=307 
69 (22) 
n=294 
37 (13) 
2  (n=834) n=434 
94 (22) 
n=400 
65 (16) 
2  (n=526) n=276 
59 (21) 
n=250 
40 (16) 
3  (n=391) n=189 
40 (21) 
n=202 
19 (9) 
3  (n=856) n=401 
89 (22) 
n=455 
80 (18) 
3  (n=551) n=252 
54 (21) 
n=299 
50 (17) 
4  (n=209) n=104 
26 (25) 
n=105 
16 (15) 
4  (n=831) n=425 
94 (22) 
n=406 
64 (16) 
4  (n=511) n=265 
61 (23) 
n=246 
44 (18) 
5  (n=137) n=65 
26 (40) 
n=72 
10 (14) 
5  (n=842) n=433 
103 (24) 
n=409 
53 (13) 
5  (n=503) n=258 
73 (28) 
n=245 
37 (15) 
SLS: Salford Lung Study; COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; FF/VI: fluticasone 
furoate/vilanterol; UC: usual care. #: the SLS asthma ICS/LABA therapy subset comprised patients whose baseline maintenance therapy per randomisation 
stratification and pre-randomisation prescription was an ICS/LABA; ¶: where 1 = most deprived, 5 = least deprived.  
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TABLE 5 Rates of patient withdrawals from study by deprivation quintile in SLS COPD and SLS asthma (total study populations and SLS asthma 
ICS/LABA therapy subset#) 
Patient withdrawal rate, n (%) 
 
 
Deprivation 
quintile¶ 
SLS COPD  
(N=2791) 
 
 
Deprivation 
quintile¶ 
SLS asthma  
(N=4218) 
 
 
Deprivation 
quintile¶ 
ICS/LABA therapy subset  
(N=2642) 
FF/VI 
(n=1396) 
UC 
(n=1395) 
FF/VI 
(n=2105) 
UC 
(n=2113) 
FF/VI 
(n=1319) 
UC 
(n=1323) 
1  (n=1453) n=731 
54 (7) 
n=722 
53 (7) 
1  (n=855) n=412 
40 (10) 
n=443 
37 (8) 
1  (n=551) n=268 
23 (9) 
n=283 
18 (6) 
2  (n=601) n=307 
26 (8) 
n=294 
14 (5) 
2  (n=834) n=434 
47 (11) 
n=400 
43 (11) 
2  (n=526) n=276 
26 (9) 
n=250 
29 (12) 
3  (n=391) n=189 
12 (6) 
n=202 
15 (7) 
3  (n=856) n=401 
32 (8) 
n=455 
38 (8) 
3  (n=551) n=252 
20 (8) 
n=299 
26 (9) 
4  (n=209) n=104 
9 (9) 
n=105 
7 (7) 
4  (n=831) n=425 
37 (9) 
n=406 
30 (7) 
4  (n=511) n=265 
23 (9) 
n=246 
18 (7) 
5  (n=137) n=65 
4 (6) 
n=72 
3 (4) 
5  (n=842) n=433 
37 (9) 
n=409 
24 (6) 
5  (n=503) n=258 
 20 (8) 
n=245 
14 (6) 
SLS: Salford Lung Study; COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; FF/VI: fluticasone 
furoate/vilanterol; UC: usual care. #: the SLS asthma ICS/LABA therapy subset comprised patients whose baseline maintenance therapy per randomisation 
stratification and pre-randomisation prescription was an ICS/LABA; ¶: where 1 = most deprived, 5 = least deprived.  
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Figure legends 
 
FIGURE 1  
Patient distribution by deprivation quintile in SLS COPD and SLS asthma (total study 
populations).#¶ 
 
SLS: Salford Lung Study; COPD: chronic obstructive pulmonary disease. #: N=2791 
and N=4218 patients with available deprivation data for SLS COPD and SLS 
asthma, respectively. Percentages are based on a denominator of the number of 
patients with available deprivation data; ¶: for deprivation quintile, 1 = most deprived, 
5 = least deprived.  
 
FIGURE 2  
Primary effectiveness outcomes by treatment group and deprivation quintile. a) SLS 
COPD: mean annual rate of moderate/severe exacerbations (PEA population; 
N=2269).#¶+ b) SLS asthma: percentage of ACT responders at week 24 (PEA 
population; N=3015).+§‖ 
 
SLS: Salford Lung Study; COPD: chronic obstructive pulmonary disease; PEA: 
primary effectiveness analysis; ACT: Asthma Control Test; FF/VI: fluticasone 
furoate/vilanterol; UC: usual care; CI: confidence interval; LS: least squares. #: 
moderate/severe exacerbations are defined as reported previously [7]; ¶: analysis 
using a general linear model assuming a negative binomial distribution, with the 
logarithm of time on treatment as an offset variable and adjusting for randomised 
treatment, baseline COPD maintenance therapy per randomisation stratification, 
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number of prior moderate/severe COPD exacerbations in the previous year, baseline 
smoking status, deprivation quintile and a randomised treatment-by-deprivation 
quintile interaction term; +: for deprivation quintile, 1 = most deprived, 5 = least 
deprived; §: ACT responders were defined as patients who achieved an ACT total 
score ≥20 and/or increase from baseline ≥3; ‖: analysis by logistic regression with 
adjustment for randomised treatment, baseline ACT total score, baseline ACT total 
score squared, asthma maintenance therapy at baseline per randomisation 
stratification, age, gender, baseline smoking status, deprivation quintile and a 
randomised treatment-by-deprivation quintile interaction term.  
 
FIGURE 3  
Percentage of ACT responders at weeks 12, 40 and 52 by treatment group stratified 
by deprivation quintile in SLS asthma (PEA population; N=3015).#¶+ 
 
ACT: Asthma Control Test; SLS: Salford Lung Study; PEA: primary effectiveness 
analysis; UC: usual care; FF/VI: fluticasone furoate/vilanterol; CI: confidence interval. 
#: ACT responders were defined as patients who achieved an ACT total score ≥20 
and/or increase from baseline ≥3; ¶: analysis by logistic regression with adjustment 
for randomised treatment, baseline ACT total score, baseline ACT total score 
squared, asthma maintenance therapy at baseline per randomisation stratification, 
age, gender, baseline smoking status, deprivation quintile and a randomised 
treatment-by-deprivation quintile interaction term; +: for deprivation quintile, 1 = most 
deprived, 5 = least deprived.  
 
